Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Gsk (GLAXF) over the last 17 years, with Q4 2025 value amounting to -$53.2 million.

  • Gsk's Gains from Investment Securities rose 7080.97% to -$53.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$121.0 million, marking a year-over-year increase of 5667.58%. This contributed to the annual value of -$121.3 million for FY2025, which is 785.27% up from last year.
  • As of Q4 2025, Gsk's Gains from Investment Securities stood at -$53.2 million, which was up 7080.97% from -$9.4 million recorded in Q3 2025.
  • In the past 5 years, Gsk's Gains from Investment Securities registered a high of -$3.8 million during Q2 2023, and its lowest value of -$588.3 million during Q4 2023.
  • Its 5-year average for Gains from Investment Securities is -$93.1 million, with a median of -$39.7 million in 2024.
  • Per our database at Business Quant, Gsk's Gains from Investment Securities soared by 8824.86% in 2021 and then tumbled by 87505.41% in 2024.
  • Gsk's Gains from Investment Securities (Quarter) stood at -$164.5 million in 2021, then tumbled by 47.63% to -$242.8 million in 2022, then plummeted by 142.3% to -$588.3 million in 2023, then surged by 69.02% to -$182.3 million in 2024, then soared by 70.81% to -$53.2 million in 2025.
  • Its Gains from Investment Securities stands at -$53.2 million for Q4 2025, versus -$9.4 million for Q3 2025 and -$30.7 million for Q2 2025.